Advertisement
RNAC vs SLDB
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RNAC is a Buy and SLDB is a Hold.
RNAC in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 14, 2026
RNAC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 44 cases where RNAC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RNAC's RSI Oscillator exited the oversold zone, 37 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for RNAC just turned positive on October 21, 2026. Looking at past instances where RNAC's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.
Following a +5.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNAC advanced for three days, in 218 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNAC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for RNAC entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.551) is normal, around the industry mean (2.988). P/E Ratio (-1.111) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (144.928) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. RNAC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNAC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
SLDB's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for SLDB turned positive on October 21, 2026. Looking at past instances where SLDB's MACD turned positive, the stock continued to rise in 40 of 45 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SLDB's RSI Indicator exited the oversold zone, 35 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 55 cases where SLDB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
Following a +8.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLDB advanced for three days, in 203 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
SLDB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day moving average for SLDB crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLDB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for SLDB entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.837) is normal, around the industry mean (2.988). P/E Ratio (-3.392) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. SLDB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLDB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
RNAC | SLDB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 68 | 64 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 28 Undervalued | 31 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 78 | 65 | |
P/E GROWTH RATING 1..100 | 20 | 19 | |
SEASONALITY SCORE 1..100 | n/a | 23 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RNAC's Valuation (28) in the Biotechnology industry is in the same range as SLDB (31). This means that RNAC’s stock grew similarly to SLDB’s over the last 12 months.
RNAC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SLDB (100). This means that RNAC’s stock grew similarly to SLDB’s over the last 12 months.
SLDB's SMR Rating (98) in the Biotechnology industry is in the same range as RNAC (100). This means that SLDB’s stock grew similarly to RNAC’s over the last 12 months.
SLDB's Price Growth Rating (65) in the Biotechnology industry is in the same range as RNAC (78). This means that SLDB’s stock grew similarly to RNAC’s over the last 12 months.
SLDB's P/E Growth Rating (19) in the Biotechnology industry is in the same range as RNAC (20). This means that SLDB’s stock grew similarly to RNAC’s over the last 12 months.
| RNAC | SLDB | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 84% | 2 days ago 85% |
| Stochastic ODDS (%) | N/A | 2 days ago 87% |
| Momentum ODDS (%) | N/A | N/A |
| MACD ODDS (%) | 2 days ago 82% | 2 days ago 89% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| Advances ODDS (%) | 2 days ago 83% | 2 days ago 79% |
| Declines ODDS (%) | 4 days ago 90% | 9 days ago 89% |
| BollingerBands ODDS (%) | 2 days ago 86% | 2 days ago 79% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RNAC’s FA Score shows that 2 FA rating(s) are green while SLDB’s FA Score has 2 green FA rating(s).
- RNAC’s FA Score: 2 green, 3 red.
- SLDB’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RNAC’s TA Score shows that 4 TA indicator(s) are bullish while SLDB’s TA Score has 5 bullish TA indicator(s).
- RNAC’s TA Score: 4 bullish, 2 bearish.
- SLDB’s TA Score: 5 bullish, 3 bearish.
Price Growth
RNAC (@Biotechnology) experienced а +1.26% price change this week, while SLDB (@Biotechnology) price change was +17.29% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.02%. For the same industry, the average monthly price growth was -18.10%, and the average quarterly price growth was -15.28%.
Reported Earning Dates
RNAC is expected to report earnings on Nov 05, 2026.
SLDB is expected to report earnings on Nov 02, 2026.
Industries' Descriptions
@Biotechnology (-1.02% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
RNAC and
Correlation & Price change
A.I.dvisor indicates that over the last year, RNAC has been closely correlated with TAOX. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if RNAC jumps, then TAOX could also see price increases.
| Ticker / NAME | Correlation To RNAC | 1D Price Change % | ||
|---|---|---|---|---|
| RNAC | 100% | +0.39% | ||
| TAOX - RNAC | 91% Closely correlated | +4.88% | ||
| PALI - RNAC | 81% Closely correlated | -2.10% | ||
| EDIT - RNAC | 46% Loosely correlated | -2.71% | ||
| NKTX - RNAC | 45% Loosely correlated | +0.57% | ||
| SLDB - RNAC | 41% Loosely correlated | +0.16% | ||
More | ||||